Company profile
ATTOVIA THERAPEUTICS, INC.
NASDAQ:ATTOBiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07833306 | phase2 | not_yet_recruiting | 2026-12-21 | 2028-08-30 | Attovia Therapeutics Inc | Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin |
| NCT07819799 | phase1 | not_yet_recruiting | 2026-12-14 | 2028-07-15 | Attovia Therapeutics Inc | Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis |
| NCT06787586 | phase1 | completed | 2025-01-14 | 2026-06-11 | Attovia Therapeutics Inc | Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus |
| NCT07205081 | phase1 | completed | 2025-10-22 | 2026-08-13 | Attovia Therapeutics Inc | Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis |
FDA applications (0)
No records yet.